Search results
Results from the WOW.Com Content Network
A dog displaying a typical clinical picture of visceral leishmaniasis. Canine leishmaniasis (LEESH-ma-NIGH-ah-sis) is a zoonotic disease (see human leishmaniasis) caused by Leishmania parasites transmitted by the bite of an infected phlebotomine sandfly. There have been no documented cases of leishmaniasis transmission from dogs to humans.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
These symptoms may develop over a few months preceding the onset of SARDS. [4] Clinical signs and disease progression vary markedly among individual animals, depending on the number and type of hormones that are increased, the degree of hormone elevation, and the age of the dog.
At the pre-specified analysis point when 42 Recurrence-free survival (RFS) events occurred among 157 participants with resected stage IIIC-IV melanoma, 22.4% (24/107) in the mRNA-4157 plus pembrolizumab arm had recurrent disease, and 40% (20/50) in the pembrolizumab arm had recurrent disease, which lead to the well-known saying: mRNA-4157 in ...
Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17] Keytruda is approved to treat melanoma and lung cancer and is produced by Merck .
Granulomatous meningoencephalitis (GME) is an inflammatory disease of the central nervous system (CNS) of dogs and, rarely, cats.It is a form of meningoencephalitis.GME is likely second only to encephalitis caused by canine distemper virus as the most common cause of inflammatory disease of the canine CNS. [1]
It occurs in humans [1] and cats, more frequently occurring in dogs. It was first described in dogs by Griffin and colleagues in 1979. [2] [3] DLE is one form of cutaneous lupus erythematosus (CLE). DLE occurs in dogs in two forms: a classical facial predominant form or generalized with other areas of the body affected.
Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly for patients with non-small cell lung cancer . [27] INCMGA00012 (MGA012) is a humanized IgG4 monoclonal antibody developed by Incyte and MacroGenics. [28] AMP-224 by AstraZeneca/MedImmune and GlaxoSmithKline [29] AMP-514 (MEDI0680) by AstraZeneca [30]